Christine Katlama

发表

Safety of non-nucleoside reverse transcriptase therapy: data from the EuroSIDA study

Andrew N. Phillips, Nina Friis-Møller, Ole Kirk, 2003 .

No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients

Vincent Calvez, Christine Katlama, V. Calvez, 2005, AIDS.

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

Luba Tchertanov, Vincent Calvez, Christine Katlama, 2008, Antimicrobial Agents and Chemotherapy.

Factors Associated with the Selection of Mutations Conferring Resistance to Protease Inhibitors (PIs) in PI-Experienced Patients Displaying Treatment Failure on Darunavir

Philippe Flandre, Vincent Calvez, Christine Katlama, 2007, Antimicrobial Agents and Chemotherapy.

Evidence of genotypic resistance diversity of archived and circulating viral strains in blood and semen of pre-treated HIV-infected men

Roland Tubiana, Franck Letourneur, Christine Katlama, 2004, AIDS.

Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C.

Christine Katlama, Dominique Thabut, Y. Ngo, 2013, Journal of hepatology.

IL-2 therapy and thymic production of naive CD4 T cells in HIV-infected patients with severe CD4 lymphopenia

Brigitte Autran, Roland Tubiana, Christine Katlama, 2003, AIDS.

Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)

Roland Tubiana, Vincent Calvez, Christine Katlama, 2004, AIDS.

Polylactic acid implants (New-Fill)® to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA

Philippe Katz, Christine Katlama, C. Katlama, 2003, AIDS.

Modulation of interleukin-7 receptor expression characterizes differentiation of CD8 T cells specific for HIV, EBV and CMV

Denis Puthier, Brigitte Autran, Christine Katlama, 2005, AIDS.

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.

Christine Katlama, Joep Lange, Adriano Lazzarin, 2003, The New England journal of medicine.

High Variability of Indinavir and Nelfinavir Pharmacokinetics in HIV-infected Patients with a Sustained Virological Response on Highly Active Antiretroviral Therapy

France Mentré, Xavier Duval, Christine Katlama, 2005, Clinical pharmacokinetics.

Call for network of Centres of Excellence in clinical research in Europe

Christine Katlama, Nathan Clumeck, 2004, The Lancet.

Characterization of genotypic determinants in HR-1 and HR-2 gp41 domains in individuals with persistent HIV viraemia under T-20

Sabine Yerly, Vincent Calvez, Christine Katlama, 2004, AIDS.

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial.

Jing Zhao, Christine Katlama, Benjamin Young, 2011, The Lancet. Infectious diseases.